

# Market Announcement

2 February 2026

---

## Cyclopharm Limited (ASX: CYC) – Trading Halt

Trading in the securities of Cyclopharm Limited ('CYC') will be halted at the request of CYC, pending the release of an announcement by CYC.

Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of:

- the commencement of normal trading on Wednesday, 4 February 2026; or
- the release of the announcement to the market.

CYC's request for a trading halt is attached below for the information of the market.

### Issued by

ASX Compliance



2 February 2026

**cyclo**medica  
**techneg**as

Listing Compliance  
Australian Securities Exchange Limited  
39 Martin Place  
Sydney NSW 2000

Cyclopharm Ltd  
ABN 74 116 931 250  
Unit 4, 1 The Crescent  
Kingsgrove NSW 2208 Australia  
T 61 2 9541 0411  
F 61 2 9543 0960  
[www.cyclopharm.com.au](http://www.cyclopharm.com.au)

[tradinghaltssydney@asx.com.au](mailto:tradinghaltssydney@asx.com.au)

### **Cyclopharm Limited (ASX: CYC) – Trading Halt Request**

Pursuant to ASX Listing Rule 17.1, Cyclopharm Limited ACN 116 931 250 (Company) requests a trading halt of the Company's securities pending the release of an announcement relating to the completion of a capital raising. The capital raising will involve a placement of new shares to institutional and sophisticated investors, followed by a share purchase plan to eligible shareholders.

The Company requests that the trading halt be effective immediately and remain in place until the earlier of the commencement of normal trading on Wednesday, 4 February 2026 or the release of an announcement by the Company in relation to the capital raising.

The Company is not aware of any reason why the trading halt should not be granted or of any other information necessary to inform the market regarding the trading halt. For any questions, please contact the undersigned on +61 2 9541 0411.

This ASX announcement was approved and authorized for release by James McBrayer, Managing Director, CEO and Company Secretary.

Yours faithfully,

#### **For more information, please contact:**

Mr James McBrayer  
Managing Director, CEO and Company Secretary  
Cyclopharm Limited  
T: +61 (02) 9541 0411

ENDS

#### **Cyclopharm Limited**

Cyclopharm is an ASX Listed radiopharmaceutical company servicing the global medical community. The Company's mission is to provide nuclear medicine and other clinicians with the ability to improve patient care outcomes. Cyclopharm achieves this objective primarily through the provision of its core radiopharmaceutical product, Technegas® used in functional lung ventilation imaging.

**Technegas®**

Technegas® technology is a structured ultra-fine dispersion of radioactive labelled carbon, produced by using dried Technetium-99m in a carbon crucible, micro furnaced for a few seconds at around 2,700° C. The resultant gas like substance is inhaled by the patient (lung ventilation) via a breathing apparatus, which then allows multiple views and tomography imaging under a gamma or single photon emission computed tomography (SPECT) camera for evaluating functional ventilation imaging. Historically used in the diagnosis of pulmonary embolism, Technegas®, together with advancements in complementary technology, multimodality imaging, and analytical software, is being used in other disease states, including COPD, asthma, pulmonary hypertension and certain interventional applications such as lobectomies in lung cancer and lung volume reduction surgery.